在体内基因毒性测试策略:第八届基因毒性测试国际研讨会 (IWGT) 的报告
Carol Beevers1, Yoshifumi Uno2, Krista Meurer3
1Corteva Agriscience, Oxford, UK.
Environmental and molecular mutagenesis
|November 9, 2023
概括
负的红细胞微核 (MN) 测试可接受,骨髓暴露足够,遵循经合组织的指导方针. 对非血造组织中的MN测定和彗星测定标准化的进一步研究是必要的.
科学领域:
- 基因毒性测试是指基因毒性测试.
- 在体内测试的体内测试.
- 监管科学是一种监管科学.
背景情况:
- 活体内工作组解决了基因毒性测试中的关键问题.
- 主题包括负微核 (MN) 测试的最大剂量,非血液构造性MN测试的验证和彗星测试挑战.
研究的目的:
- 在体内基因毒性测试的可接受实践上达成共识.
- 评估MN和彗星测定的验证状态和适用性.
主要方法:
- 专家小组讨论和共识建设.
- 审查现有数据和指导方针 (OECD TG 474).
主要成果:
- 在足够的骨髓暴露下接受负性红细胞MN研究的标准上达成协议.
- 肝脏MN检测验证了经合组织TG的发展,但需要研究年龄影响.
- 胃肠道MN测定对特定的新原体有用;考虑了OECD TG474的附录.
- 对彗星测定数据的解释需要对历史对照数据 (HCD) 和细胞毒性标记者保持谨慎.
结论:
- 在特定暴露条件下,负红细胞MN研究是可以接受的.
- 对非造血性MN试验和彗星试验需要进一步的验证和标准化.
- 对于彗星测定解释,需要标准化细胞毒性标记物.
相关概念视频
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
In-vitro Mutagenesis
14.0K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.0K


